Lifeward CEO Mark Grant departs, Josh Hexter named interim chief

Lifeward Ltd. disclosed in an 8-K dated August 31, 2026 that Mark Grant will depart from his positions as President and Chief Executive Officer of the company and as a member of its Board of Directors, effective August 31, 2026, following a separation agreement entered into that same day.¹ The filing states that Grant's exit does not stem from any disagreement with the company over its operations, policies or practices.¹

To manage the handoff, the company entered into a consulting agreement with Grant effective September 1, 2026, under which he will remain as a Senior Advisor through September 30, 2026, offering transition help and other consulting work for a $40,000 fee.¹ Under the separation terms, Grant's unvested equity awards will stop vesting as of August 31, 2026 and be forfeited, and he will not receive cash severance or continued benefits beyond accrued compensation and the consulting fee.¹

The Board named Josh Hexter, age 56, as Interim Chief Executive Officer and principal executive officer, effective September 1, 2026.¹ Hexter's other role is disclosed in the filing: he currently serves as Chief Operating and Business Officer of Oramed Pharmaceuticals Inc., described as the controlling shareholder of Lifeward, a post he has held since September 2019.¹ The company said Hexter will substantially reduce his Oramed duties, to roughly 5% of his current workload, after taking the Lifeward role.¹ His pay package includes a gross monthly base salary of NIS 100,000 plus a monthly commuting allowance of NIS 5,000 or a company car.¹

Separately, the filing announced that Rami Aviram, age 47, was appointed Chief Financial Officer effective November 1, 2026, succeeding Almog Adar, whose departure takes effect September 30, 2026.¹ Aviram most recently served as Chief Financial Officer of Beewise Technologies Ltd. from August 2024 to October 2026.¹